Investing.com - Haemonetics (NYSE: HAE) reported second quarter EPS of $1.12, $0.05 better than the analyst estimate of $1.07. Revenue for the quarter came in at $346M versus the consensus estimate of $342.58M.
Guidance
Haemonetics sees FY 2025 EPS of $4.45-$4.75 versus the analyst consensus of $4.59.
Haemonetics's stock price closed at $78.16. It is up 1.47% in the last 3 months and up 0.23% in the last 12 months.
Haemonetics saw 1 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Haemonetics's stock price’s past reactions to earnings here.
According to InvestingPro, Haemonetics's Financial Health score is "great performance".
Check out Haemonetics's recent earnings performance, and Haemonetics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar